Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aldosterone receptor antagonists].

O Muller1, D Firsov, C Seydoux

  • 1Service de cardiologie, CHUV, 1011 Lausanne. olivier.muller@chuv.ch

Revue Medicale Suisse
|July 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Informing robot design through early public engagement: lay perceptions of soft versus rigid socially assistive and rescue robots.

Frontiers in robotics and AI·2026
Same author

Engineering vascular potassium transport increases yield and drought resilience of cassava.

Nature plants·2025
Same author

Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2024
Same author

What is the best surgical option after failure of graciloplasty in patients with recurrent rectovaginal fistula? A study of 19 consecutive patients.

Techniques in coloproctology·2022
Same author

Determinants of the use of insecticide-treated mosquito nets in pregnant women: a mixed-methods study in Ghana.

International health·2022
Same author

[Erratum to: Interdisciplinary neurovascular networks: state of the art].

Der Nervenarzt·2020
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Mineralocorticoid receptor antagonists (MRAs) are crucial for managing cardiovascular disease. Eplerenone, a novel MRA, offers improved safety by avoiding side effects like gynecomastia, making it a recommended treatment for heart failure.

Area of Science:

  • Cardiovascular physiology and pathology
  • Endocrinology and hormone signaling
  • Pharmacology of cardiovascular drugs

Context:

  • Mineralocorticoid signaling significantly impacts cardiovascular health and disease progression.
  • Clinical and experimental data link mineralocorticoid hormones to increased cardiovascular morbidity and mortality.
  • Mineralocorticoid receptor antagonists (MRAs) are re-emerging as critical therapeutic agents.

Purpose:

  • To highlight the role of mineralocorticoid signaling in cardiovascular disease.
  • To introduce eplerenone as a novel, safer mineralocorticoid receptor antagonist.
  • To summarize guideline recommendations for MRA use in heart failure.

Summary:

  • Mineralocorticoid hormones are implicated in cardiovascular pathophysiology, contributing to morbidity and mortality.

Related Experiment Videos

  • Eplerenone, a new MRA, provides an alternative to older agents by lacking side effects such as gynecomastia.
  • Guidelines from European and American cardiology societies recommend MRAs for specific heart failure types, including NYHA Class III-IV and post-infarct heart failure with reduced ejection fraction (<40%), based on RALES and EPHESUS studies.

    • Impact:

    • Eplerenone offers a safer therapeutic option for patients with cardiovascular conditions.
    • The use of MRAs is supported by major cardiology guidelines for managing heart failure.
    • Understanding mineralocorticoid signaling is key to developing future cardiovascular therapies.